AMENDMENTS TO THE SPECIFICATION

Page 1

Before line 1 of the specification **(after the Title)**, please insert the following new paragraph:

-- This application is a national phase under 35 U.S.C § 371 of PCT International Application No. PCT/SE2004/002034 which has an International filing date of December 30, 2004, which designated the United States of America. In addition, this application claims priority to Application No.: 0400021-2 filed in Sweden, which was filed on January 8, 2004 and Application No.: 0400585-6, filed in Sweden, which was filed on March 9, 2004.--

Page 2

Please replace the paragraph beginning on line 7 with the following new paragraph:

-- Our co-pending, but as of the priority date unpublished PCT application WO 04/021969 discloses compounds generally of the formula I above, but wherein R^2 is pyrid-2-yl substituted at the 5 position with a group of the formula $-(CHR_{11})_p$-E-$(CHR_{11})_q$-R_{10} where E is E is $-CH_2$-, -CHOH-, -C=O-, $-NR_9$-, –O-, -S-, $-S(=O)_2$-;

p and q are independently 0, 1 or 2, where $p+q \leq 2$;

R_{10} is a monocyclic ring which is optionally substituted with halo, cyano, morpholinomethyl- or morpholinoketo-; and

R_{11} is independently H, C_1-C_3 alkyl, halo substituted C_1-C_3alkyl or hydroxy. - -

Please replace the paragraph beginning on line 23 and ending on page 4 with the following new paragraph:

--In accordance with a first aspect of the invention there are provided compounds of the formula Z:



where;

A is CH or N;

R_1 is a substituent to a carbon atom in the ring containing A selected from

$-S(=O)_pRa$,

where Ra is $-C_1$-C_4 alkyl, -ORx, -NRxRx, -NHNRxRx, -NHNHC(=O)ORx, -NRxOH;

-C(=O)-Rb,

where Rb is $-C_1$-C_4-alkyl, ORx, -NRxRx, -NRxNRxRx, $-NHC_1$-C_3-alkyl-C(=O)ORx;

-NRxRc,

where Rc is H, C_1-C_4 alkyl, -NRxRx; -C(=O)Rd, -CN, $S(=O)_pRx$

where Rd is Rd is C_1-C_4-alkyl, -ORx, -NRxRx

$-C_1$-C_3-alkyl-O-C_1-C_3alkylC(=O)ORx;

$-C_1$-C_3-alkyl-COORx;

$-C_1$-C_3alkyl-OH or C_1-C_4 alkyl ethers or esters thereof;

$-(O-C_1-C_3alkyl)_q$-O-Rx;

a 5 or 6 membered aromatic ring having 1-3 hetero atoms;

p and q are independently selected from 1 or 2;

Rx is independently selected from H, C_1-C_4 alkyl, or acetyl; or a pair of Rx can together with the adjacent N atom form a pyrrolidine, piperidine, piperazine or morpholine ring;

R_2 is a substituent to a carbon atom in the ring containing A and is H, halo, cyano, C_1-C_4-alkyl, haloC_1-C_4-alkyl;

L is –O-, -S(=O)$_r$- or –CH_2-, where r is 0, 1 or 2;

R_3 is H, C_1-C_3 alkyl;

R_4-R_7 are independently selected from H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, haloC_1-C_6 alkyl, C_1-C_6 alkanoyl, haloC_1-C_6 alkanoyl, C_1-C_6 alkoxy, haloC_1-C_6 alkoxy, C_1-C_6 alkyloxyC_1-C_6 alkyl, haloC_1-C_6 alkyloxyC_1-C_6 alkyl, hydroxyC_1-C_6 alkyl, aminoC_1-C_6 alkyl, carboxyC_1-C_6 alkyl, cyanoC_1-C_6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;

X is –$(CR_8R_8')_n$-D-$(CR_8R_8')_m$-;

T is O or S;

D is a bond, –NR_9-, –O-, -S-, -S(=O)- or –$S(=O)_2$-;

n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;

R_8 and R_8' are independently H, C_1-C_3 alkyl, haloC_1-C_3alkyl, hydroxy, or R_8 and R_8' together with their adjacent C atom is –C(=O)-

R_9 is independently H, C_1-C_3 alkyl;

and pharmaceutically acceptable salts and prodrugs thereof,

with the proviso that R_1 as –C(=O)Rb is not morpholinoketo-.--

Page 4

Please replace the paragraph beginning on line 13 with the following new paragraph:

-- The currently preferred value for T is O, that is a urea derivative, although T as S (ie a thiourea derivative) is also highly potent. - -

Page 7

Please the replace structures beginning on line 4 with the following new structures:

--



--